Assessment report for Sylvant (siltuximab), 20 March 2014, EMA/CHMP/258608/2014.
"No environmental risk assessment was submitted. In accordance with the Guideline on the environmental risk assessment (ERA) of medicinal products for human use [EMEA/CHMP/SWP/4447/00], peptides and proteins are excluded from the need for an environmental risk assessment. Therefore, an ERA for siltuximab is not required."
Fass environmental information for Sylvant from Janssen (downloaded 2019-09-04).
The use of amino acids, proteins and peptides is not expected to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm